LTIP112A - The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs - Google Patents

The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs

Info

Publication number
LTIP112A
LTIP112A LTIP112A LTIP112A LTIP112A LT IP112 A LTIP112 A LT IP112A LT IP112 A LTIP112 A LT IP112A LT IP112 A LTIP112 A LT IP112A LT IP112 A LTIP112 A LT IP112A
Authority
LT
Lithuania
Prior art keywords
medetomidine
regulate
rate
optically active
drugs
Prior art date
Application number
LTIP112A
Inventor
Harry Jalonen
Arto Johannes Karjalainen
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Publication of LTIP112A publication Critical patent/LTIP112A/en
Publication of LT3130B publication Critical patent/LT3130B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Salts of medetomidine and optically active enantiomers, thereof, particularly the d-enantiomer are disclosed. These salts may be used to regulate the rate of the transdermal administration of active drugs. The transdermal delivery system comprises a drug impermeable backing layer and an adhesive layer wherein the medetomidine is dispersed throughout the adhesive layer.
LTIP112A 1991-05-31 1992-05-29 The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs LT3130B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111732A GB9111732D0 (en) 1991-05-31 1991-05-31 The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs

Publications (2)

Publication Number Publication Date
LTIP112A true LTIP112A (en) 1994-07-15
LT3130B LT3130B (en) 1994-12-25

Family

ID=10695876

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP112A LT3130B (en) 1991-05-31 1992-05-29 The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs

Country Status (17)

Country Link
US (1) US5438067A (en)
EP (1) EP0587819B1 (en)
JP (2) JP3483881B2 (en)
AT (1) ATE149090T1 (en)
AU (1) AU1798192A (en)
CA (1) CA2110161C (en)
DE (1) DE69217658T2 (en)
EE (1) EE03053B1 (en)
FI (1) FI104948B (en)
GB (2) GB9111732D0 (en)
IE (1) IE67168B1 (en)
LT (1) LT3130B (en)
LV (1) LV10047B (en)
NO (1) NO303818B1 (en)
NZ (1) NZ242717A (en)
WO (1) WO1992021338A1 (en)
ZA (1) ZA923395B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883115A (en) * 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
IT1290255B1 (en) * 1997-02-05 1998-10-22 Wallcovering Pubblicita S R L SHAPED SUPPORT ADHERING TO THE SKIN FOR THE SALE OF COSMETIC OR PHARMACOLOGICAL SUBSTANCES AND METHOD FOR ITS MANUFACTURE
DE19936395C2 (en) 1999-08-03 2002-07-18 Antonia Buntz Cosmetic plasters and method for lifting the female breast by means of such a cosmetic plaster and its use
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
KR101859486B1 (en) * 2009-05-15 2018-06-28 레크로파마, 인코포레이티드 Sublingual Dexmedetomidine Compositions and Methods of Use Thereof
AU2011204315A1 (en) * 2010-01-08 2012-08-02 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
US20120202863A1 (en) * 2011-02-03 2012-08-09 Gerald Horn Compositions and methods for treatment of glaucoma
SG11201403094TA (en) 2011-12-11 2014-10-30 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
KR20160055934A (en) * 2013-10-07 2016-05-18 테이코쿠 팔마 유에스에이, 인코포레이티드 Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
KR101831290B1 (en) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
KR101891186B1 (en) * 2013-10-07 2018-08-24 테이코쿠 팔마 유에스에이, 인코포레이티드 Methods and compositions for managing pain comprising dexmedetomidine transdermal compositions
RU2646512C2 (en) * 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Dexmedetomidine transdermal delivery devices and methods for using the same
RU2648449C2 (en) * 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
JP6469587B2 (en) 2013-12-18 2019-02-13 丸石製薬株式会社 Water-containing patch
RU2723761C1 (en) 2016-10-31 2020-06-17 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Methods for pain relief using dexmedetomidine transdermal delivery devices
CN111346072B (en) * 2018-12-21 2022-05-27 宜昌人福药业有限责任公司 Transdermal drug delivery pharmaceutical composition and preparation method thereof
AU2020264808B2 (en) 2019-05-01 2025-01-02 Clexio Biosciences Ltd. Methods of treating pruritus
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
TWI772807B (en) 2019-05-27 2022-08-01 日商救急藥品工業股份有限公司 External preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101114B (en) * 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FI864570A0 (en) * 1986-11-11 1986-11-11 Farmos Oy THERAPEUTIC ANVAENDBAR FOERENING.
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5304569A (en) * 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure

Also Published As

Publication number Publication date
GB2256367A (en) 1992-12-09
FI935351L (en) 1993-11-30
DE69217658D1 (en) 1997-04-03
JPH06507888A (en) 1994-09-08
GB9211033D0 (en) 1992-07-08
CA2110161A1 (en) 1992-12-10
GB9111732D0 (en) 1991-07-24
ATE149090T1 (en) 1997-03-15
US5438067A (en) 1995-08-01
NO303818B1 (en) 1998-09-07
CA2110161C (en) 2004-08-03
FI935351A0 (en) 1993-11-30
LT3130B (en) 1994-12-25
WO1992021338A1 (en) 1992-12-10
ZA923395B (en) 1993-03-31
NO934323L (en) 1993-11-29
DE69217658T2 (en) 1997-07-03
EE03053B1 (en) 1997-12-15
LV10047B (en) 1995-02-20
GB2256367B (en) 1995-03-15
NZ242717A (en) 1994-03-25
FI104948B (en) 2000-05-15
JP2003327531A (en) 2003-11-19
EP0587819B1 (en) 1997-02-26
AU1798192A (en) 1993-01-08
LV10047A (en) 1994-05-10
IE67168B1 (en) 1996-03-06
IE921937A1 (en) 1992-12-02
JP3483881B2 (en) 2004-01-06
EP0587819A1 (en) 1994-03-23
NO934323D0 (en) 1993-11-29

Similar Documents

Publication Publication Date Title
GB2256367B (en) Transdermal administration of salts of medetomidine
AU679032B2 (en) Transdermal therapeutic system with galanthamine as active ingredient
DK581685A (en) TRANSDERIMAL SYSTEM FOR TIMOLOL ADMINISTRATION
FI952269A0 (en) Skin-penetrating therapeutic system for application of physostigmine to the skin and method of preparation of the system
TW273516B (en) Adhesive matrix-type transdermal therapeutic set for motion sickness

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20050529